Memorial Hospital Research Laboratories

The Charles Rudin Lab

Research

Charles M. Rudin, MD, PhD

Professor

Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.

Featured News

In the Lab

Scientists Home in on Treatment Advance for Chemotherapy-Resistant Small Cell Lung Cancer

Monday, February 13, 2017

Publications

Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, Baslan T, Tian S, Chen HA, Romesser PB, Poirier JT, Rudin CM, de Stanchina E, Manchado E, Sherr CJ, Lowe SW. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 362(6421):1416-1422. 2018.

Laird JH, Lok BH, Ma J, Bell A, de Stanchina E, Poirier JT, Rudin CM. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Clin Cancer Res. 24(20):5143-5152. 2018.

Miles LA, Burga LN, Gardner EE, Bostina M, Poirier JT, Rudin CM. Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley Virus. J Clin Invest 127:2957-67, 2017.

Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, Massion PP, Rudin CM, Poirier JT. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell 31: 286-99, 2017.

Poirier JT, Gardner EE, Connis N, Moreira AL, de Stanchina E, Hann CL, Rudin CM. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene 2015; in press.

View All Publications

People

Charles M. Rudin, MD, PhD

Professor

Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.
MD, PhD, University of Chicago Pritzker School of Medicine

rudinc@mskcc.org: Email Address
View physician profile: Physician profile

Members

Triparna Sen, PhD — Triparna Sen
Assistant Attending/Lab Co-Director

Nisarg Shah
Senior Research Assistant/Lab Manager

Andrew Chow
Assistant Attending, Thoracic Oncology Service

W. Victoria Lai — Victoria Lai
Assistant Attending, Thoracic Oncology Service

Michael Offin, MD — Michael Offin
Assistant Attending, Thoracic Oncology Service

Álvaro Quintanal Villalonga
Research Fellow

Lab Alumni

Christopher Hulton, BS, MS — Christopher Hulton
Research Scientist at C4 Therapeutic, Watertown, Massachusetts

Lab Affilations

Open Positions

Career Opportunities

We are looking for a highly motivated postdoctoral research fellow with a Ph.

Apply now

Get in Touch

rudinc@mskcc.org

Lab Head Email

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Charles M. Rudin discloses the following relationships and financial interests:

AbbVie
Provision of Services
Amgen
Provision of Services (uncompensated)
Ascentage Pharma
Provision of Services
Astra Zeneca
Provision of Services
Bridge Medicines
Provision of Services (uncompensated)
Celgene
Provision of Services
Chugai Pharmaceuticals
Provision of Services
Daiichi Sankyo
Provision of Services

Elucida Oncology
Provision of Services (uncompensated)
Genentech
Provision of Services
Harpoon Therapeutics, Inc.
Provision of Services
Loxo Oncology
Provision of Services
MORE Health, Inc
Provision of Services
Roche
Provision of Services
SynDevRx Inc
Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

View all disclosures